Erythropoiesis

The body's busiest assembly line

Red blood cells do not divide and cannot repair themselves — they have no nucleus and no machinery for it. A circulating erythrocyte lasts about 120 days before its membrane stiffens and the spleen culls it. To hold the count steady, the marrow must replace every cell it loses, which works out to roughly 2 million red cells per second, or about 200 billion per day. Erythropoiesis is that replacement line, and it lives in the red marrow of the axial skeleton — the vertebrae, sternum, ribs, pelvis, and skull — which in adults has largely retired the long-bone marrow to fat.

The whole sequence runs on demand. The marrow can idle along at baseline or, when oxygen delivery falls, throw its output up to tenfold within a week or two. That dynamic range — and the hormone that sets it — is what makes erythropoiesis one of the most elegant feedback loops in physiology.

From stem cell to red cell

Erythropoiesis begins with a hematopoietic stem cell that commits down the myeloid path and then narrows to the erythroid lineage. The earliest committed progenitors are colony-forming units: the burst-forming unit-erythroid (BFU-E) and the more mature colony-forming unit-erythroid (CFU-E). The CFU-E is the cell most dependent on erythropoietin for survival, and it gives rise to the first morphologically recognizable precursor, the proerythroblast.

From there the cell passes through a defined morphological sequence, each stage smaller than the last as the nucleus condenses and hemoglobin fills the cytoplasm:

• Proerythroblast — large cell, deep-blue cytoplasm, prominent nucleoli; the last stage before hemoglobin synthesis takes over.
• Basophilic erythroblast — intensely blue cytoplasm dense with ribosomes gearing up for hemoglobin production.
• Polychromatic erythroblast — the last dividing stage; cytoplasm turns gray-violet as pink hemoglobin mixes with blue ribosomes.
• Orthochromatic erythroblast — cytoplasm is now salmon-pink (mostly hemoglobin); the nucleus is small, dense, and about to be expelled.
• Reticulocyte — anucleate, still carrying residual ribosomal RNA; released into blood and matures in 1-2 days.
• Erythrocyte — the mature biconcave disc, ~7-8 µm across, ~33% hemoglobin by weight.

The defining moment is enucleation: the orthochromatic erythroblast pushes its condensed nucleus to one edge and pinches it off, wrapped in a thin rind of cytoplasm. Resident macrophages — the centerpiece of the marrow's "erythroblastic island," around which the maturing precursors cluster — engulf and recycle the extruded nuclei. Losing the nucleus is what gives the red cell its space for hemoglobin and its deformable biconcave shape, but it is also why the cell is mortal: with no DNA, it cannot renew its enzymes, and once its protective machinery wears down it is destined for the spleen.

EPO: the throttle, and how the kidney reads oxygen

The rate of erythropoiesis is set almost entirely by a single hormone, erythropoietin (EPO). EPO is a 30.4-kDa glycoprotein made chiefly by peritubular interstitial fibroblast-like cells in the cortex of the kidney (the fetal liver is the major source before birth, and the adult liver contributes a minor fraction). It does not stimulate cell division so much as it prevents death: EPO binds its receptor on CFU-E cells and early erythroblasts, triggering JAK2/STAT5 signaling that suppresses apoptosis. Deprived of EPO, the vast majority of these progenitors undergo programmed cell death; bathed in EPO, almost all of them survive and mature. By dialing the survival fraction up or down, the body finely titrates how many red cells reach the circulation.

The trigger is oxygen. The kidney behaves as the body's oxygen sensor because its EPO-producing cells sit where oxygen delivery and consumption are tightly matched. The molecular switch is the hypoxia-inducible factor system. In normal oxygen, prolyl-hydroxylase enzymes (using oxygen as a co-substrate) hydroxylate HIF-α, marking it for destruction by the von Hippel-Lindau ubiquitin ligase. When oxygen falls, those hydroxylases stall, HIF-2α escapes degradation, and it switches on the EPO gene. Serum EPO, normally only a few to a few dozen mU/mL, can climb past 1000 mU/mL in severe anemia, and rises severalfold within a day at altitude. This is the loop: low oxygen → HIF stabilization → EPO release → marrow rescue → more red cells → more oxygen carried → loop quiets.

The supply chain: iron, B12, folate, and hepcidin

EPO sets the pace, but the line stalls without raw materials. Each red cell carries about 270 million hemoglobin molecules, and each hemoglobin needs four iron atoms at the center of its heme groups. Iron is therefore the rate-limiting substrate, and the body recycles it aggressively — splenic macrophages strip iron from old red cells and ship it back to the marrow, covering the great majority of daily need; dietary absorption replaces only the small amount lost.

Iron availability is gated by the liver hormone hepcidin, which binds and degrades the only known cellular iron exporter, ferroportin. High hepcidin locks iron inside macrophages and enterocytes, starving erythropoiesis even when total body iron is plentiful — the mechanism behind the anemia of chronic disease, where inflammatory cytokines drive hepcidin up. Conversely, active erythropoiesis releases erythroferrone, which suppresses hepcidin and opens the iron gates.

Vitamin B12 (cobalamin) and folate are needed for the DNA synthesis that powers the rapid divisions of maturation. Without them, nuclear maturation lags behind cytoplasmic growth — producing large, defective megaloblastic precursors that die in the marrow (ineffective erythropoiesis) and oversized macrocytic red cells in the blood.

The numbers that define normal

Clinicians read erythropoiesis through a handful of standard values. Hemoglobin runs roughly 13.5-17.5 g/dL in men and 12.0-15.5 g/dL in women; hematocrit about 41-50% and 36-44% respectively. Mean corpuscular volume (MCV) — the average red cell size — normally sits at 80-100 femtoliters and is the first sorting key in anemia: low (microcytic) points toward iron deficiency or thalassemia, high (macrocytic) toward B12/folate deficiency. The single most informative marker of marrow effort is the reticulocyte count: normally 0.5-2.5% (about 25,000-75,000/µL), it should rise sharply when anemia is met by a working marrow.

Effective vs. ineffective erythropoiesis

The most useful clinical distinction is whether the marrow's furious activity actually delivers cells to the bloodstream. In a healthy response to anemia, erythropoiesis is effective: precursors mature and reach circulation, and the reticulocyte count climbs. In several diseases the marrow is hypercellular and busy but the precursors die before they finish — ineffective erythropoiesis — so the reticulocyte count stays inappropriately low despite the anemia.

Feature	Effective erythropoiesis (e.g. response to acute blood loss / hemolysis)	Ineffective erythropoiesis (e.g. β-thalassemia major, megaloblastic anemia, MDS)
Marrow precursors	Mature and exit normally	Hyperplastic but die in the marrow (intramedullary apoptosis)
Reticulocyte response to anemia	High — marrow is delivering cells	Inappropriately low for the degree of anemia
Marrow cellularity	Expanded, productive	Expanded but wasteful
Iron handling	Iron recycled and used	Erythroferrone suppresses hepcidin → iron overload over time
Typical settings	Bleeding, hemolytic anemia, altitude, EPO therapy	Thalassemia, B12/folate deficiency, myelodysplastic syndrome

This is why a thalassemia patient can have a packed, working-looking marrow and still be profoundly anemic — and why the chronic iron overload in thalassemia is driven not by transfusion alone but by the ineffective erythropoiesis signaling the gut to keep absorbing iron.

Where erythropoiesis goes wrong — and how medicine intervenes

• Chronic kidney disease. As kidney tissue is lost, EPO output falls and a normochromic, normocytic anemia develops. Treatment is recombinant EPO or its long-acting analogues (epoetin, darbepoetin), or newer oral HIF prolyl-hydroxylase inhibitors that mimic hypoxia. Hemoglobin targets are deliberately modest (~10-11 g/dL) because overcorrection raises thrombosis and stroke risk.
• Iron deficiency. The world's most common anemia. The marrow has the drive but not the bricks, producing small, pale (microcytic, hypochromic) cells and an inadequate reticulocyte response.
• Anemia of chronic disease. Inflammation raises hepcidin, locking iron away from the marrow and blunting the EPO response despite normal or high iron stores.
• Polycythemia vera. A JAK2 V617F mutation makes erythroid progenitors EPO-independent, so the marrow overproduces red cells and serum EPO is characteristically low — the mirror image of the secondary polycythemia seen with chronic hypoxia, where EPO is high.
• Doping. Recombinant EPO and blood transfusion both raise oxygen-carrying capacity for endurance sport; the thickened blood carries a real thrombotic risk, which is why anti-doping testing screens for both.
• Marrow failure. Aplastic anemia and chemotherapy suppress the precursors directly, so even abundant EPO and iron cannot rescue output.

This article is educational and is not medical advice. Anemia and disorders of red cell production have many causes; diagnosis and treatment require evaluation by a qualified clinician.